Mezuk Briana
Department of Epidemiology, University of Michigan School of Public Health, 109 Observatory, 3644 SPH Tower, Ann Arbor, MI 48109, USA.
Clin Rev Bone Miner Metab. 2008 Dec;6(3-4):101-113. doi: 10.1007/s12018-009-9025-y.
The nature of the relationship between affective disorders, bone mineral density (BMD), and bone metabolism is unresolved, although there is growing evidence that many medications used to treat affective disorders are associated with low BMD or alterations in neuroendocrine systems that influence bone turnover. The objective of this review is to describe the current evidence regarding the association of unipolar and bipolar depression with BMD and indicators of bone metabolism, and to explore potential mediating and confounding influences of those relationships. The majority of studies of unipolar depression and BMD indicate that depressive symptoms are associated with low BMD. In contrast, evidence regarding the relationship between bipolar depression and BMD is inconsistent. There is limited but suggestive evidence to support an association between affective disorders and some markers of bone turnover. Many medications used to treat affective disorders have effects on physiologic systems that influence bone metabolism, and these conditions are also associated with a range of health behaviors that can influence osteoporosis risk. Future research should focus on disentangling the pathways linking psychotropic medications and their clinical indications with BMD and fracture risk.
情感障碍、骨矿物质密度(BMD)和骨代谢之间关系的本质尚未明确,尽管越来越多的证据表明,许多用于治疗情感障碍的药物与低骨密度或影响骨转换的神经内分泌系统改变有关。本综述的目的是描述目前关于单相和双相抑郁症与骨密度及骨代谢指标之间关联的证据,并探讨这些关系中潜在的中介和混杂影响。大多数关于单相抑郁症和骨密度的研究表明,抑郁症状与低骨密度有关。相比之下,关于双相抑郁症与骨密度之间关系的证据并不一致。有有限但具有启发性的证据支持情感障碍与一些骨转换标志物之间存在关联。许多用于治疗情感障碍的药物会对影响骨代谢的生理系统产生作用,而且这些病症还与一系列可能影响骨质疏松风险的健康行为有关。未来的研究应侧重于理清将精神药物及其临床适应症与骨密度和骨折风险联系起来的途径。